

**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**LISTING OF CLAIMS:**

1.-5. (Canceled)

6. (Currently Amended) A method for slowing the progression of toward diabetic retinopathy in a diabetic not suffering from diabetic retinopathy which comprises administering to said diabetic an amount of a carbonic anhydrase inhibitor sufficient to slow the progression of toward diabetic retinopathy.

7.-11. (Canceled)

12. (Previously Presented) A method according to Claim 6, wherein the carbonic anhydrase inhibitor is administered ophthalmically to the eye or eyes.

13. (Previously Presented) A method according to Claim 6, wherein the carbonic anhydrase inhibitor is administered systemically.

14. (Original) A method according to Claim 13, wherein the carbonic anhydrase inhibitor is administered orally.

15. (Original) A method according to Claim 13, wherein the carbonic anhydrase inhibitor is administered parenterally.
16. (Previously Presented) A method according to Claim 6, wherein the carbonic anhydrase inhibitor is dorzolamide.
17. (Previously Presented) A method according to Claim 6, wherein the carbonic anhydrase inhibitor is acetazolamide.
18. (Previously Presented) A method according to Claim 6, wherein the carbonic anhydrase inhibitor is brinzolamide.
19. (Previously Presented) A method according to Claim 6, wherein the carbonic anhydrase inhibitor is methazolamide.
20. (Previously Presented) A method according to Claim 6, wherein the carbonic anhydrase inhibitor is ethoxzolamide.
21. (Previously Presented) A method according to Claim 6, wherein the carbonic anhydrase inhibitor is butazolamide.
22. (Previously Presented) A method according to Claim 6, wherein the carbonic anhydrase inhibitor is dichlorphenamide.

23. (Previously Presented) A method according to Claim 6, wherein the carbonic anhydrase inhibitor is flumethiazide.

24. (Original) A method according to Claim 12, wherein the carbonic anhydrase inhibitor is dorzolamide, acetazolamide, methazolamide, ethoxzolamide or brinzolamide.

25. (Original) A method according to Claim 14, wherein the carbonic anhydrase inhibitor is dorzolamide, acetazolamide, methazolamide, ethoxzolamide or brinzolamide.

26. (Original) A method according to Claim 15, wherein the carbonic anhydrase inhibitor is dorzolamide or brinzolamide.

27.-30. (Canceled)

31. (Currently Amended) A method for slowing the progression of toward diabetic retinopathy in a diabetic not suffering from diabetic retinopathy which comprises administering to said diabetic an amount of a carbonic anhydrase inhibitor sufficient to slow the progression of toward diabetic retinopathy, said carbonic anhydrase inhibitor being the sole active agent administered to slow the progression of diabetic retinopathy.

32.-36. (Canceled)

37. (Previously Presented) A method according to Claim 31, wherein the carbonic anhydrase inhibitor is administered ophthalmically to the eye or eyes.

38. (Previously Presented) A method according to Claim 31, wherein the carbonic anhydrase inhibitor is administered systemically.

39. (Previously Presented) A method according to Claim 38, wherein the carbonic anhydrase inhibitor is administered orally.

40. (Previously Presented) A method according to Claim 38, wherein the carbonic anhydrase inhibitor is administered parenterally.

41. (Previously Presented) A method according to Claim 31, wherein the carbonic anhydrase inhibitor is dorzolamide.

42. (Previously Presented) A method according to Claim 31, wherein the carbonic anhydrase inhibitor is acetazolamide.

43. (Previously Presented) A method according to Claim 31, wherein the carbonic anhydrase inhibitor is brinzolamide.

44. (Previously Presented) A method according to Claim 31, wherein the carbonic anhydrase inhibitor is methazolamide.

45. (Previously Presented) A method according to Claim 31, wherein the carbonic anhydrase inhibitor is ethoxzolamide.

46. (Previously Presented) A method according to Claim 31, wherein the carbonic anhydrase inhibitor is butazolamide.

47. (Previously Presented) A method according to Claim 31, wherein the carbonic anhydrase inhibitor is dichlorphenamide.

48. (Previously Presented) A method according to Claim 31, wherein the carbonic anhydrase inhibitor is flumethiazide.

49. (Previously Presented) A method according to Claim 37, wherein the carbonic anhydrase inhibitor is dorzolamide, acetazolamide, methazolamide, ethoxzolamide or brinzolamide.

50. (Previously Presented) A method according to Claim 39, wherein the carbonic anhydrase inhibitor is dorzolamide, acetazolamide, methazolamide, ethoxzolamide or brinzolamide.

51. (Previously Presented) A method according to Claim 40, wherein the carbonic anhydrase inhibitor is dorzolamide or brinzolamide.